BYSI [NASD]
BeyondSpring Inc.
Index- P/E- EPS (ttm)-1.65 Insider Own65.16% Shs Outstand39.05M Perf Week-5.69%
Market Cap46.21M Forward P/E- EPS next Y-1.75 Insider Trans0.00% Shs Float13.56M Perf Month-36.61%
Income-64.20M PEG- EPS next Q-0.23 Inst Own32.00% Short Float30.24% Perf Quarter-53.23%
Sales1.40M P/S33.01 EPS this Y19.10% Inst Trans60.91% Short Ratio12.77 Perf Half Y-90.84%
Book/sh0.68 P/B1.71 EPS next Y-48.30% ROA-71.40% Target Price14.32 Perf Year-88.97%
Cash/sh1.81 P/C0.64 EPS next 5Y- ROE-133.10% 52W Range1.13 - 33.00 Perf YTD-74.39%
Dividend- P/FCF- EPS past 5Y-17.10% ROI-244.40% 52W High-96.48% Beta1.21
Dividend %- Quick Ratio5.00 Sales past 5Y- Gross Margin- 52W Low2.65% ATR0.14
Employees103 Current Ratio5.00 Sales Q/Q50.00% Oper. Margin- RSI (14)30.69 Volatility9.49% 10.35%
OptionableYes Debt/Eq0.06 EPS Q/Q53.00% Profit Margin- Rel Volume0.50 Prev Close1.15
ShortableYes LT Debt/Eq0.00 EarningsApr 14 BMO Payout- Avg Volume321.29K Price1.16
Recom2.80 SMA20-18.77% SMA50-38.61% SMA200-87.02% Volume160,598 Change0.87%
Dec-02-21Downgrade Jefferies Buy → Hold $38 → $5
Dec-02-21Downgrade BofA Securities Buy → Underperform $45 → $5
Dec-01-21Downgrade William Blair Outperform → Mkt Perform
Dec-01-21Downgrade H.C. Wainwright Buy → Neutral
Sep-09-21Initiated Robert W. Baird Outperform $50
Aug-04-21Upgrade H.C. Wainwright Neutral → Buy $100
Apr-05-21Downgrade H.C. Wainwright Buy → Neutral
Jan-11-21Initiated BofA Securities Buy $25
Dec-29-20Initiated Evercore ISI Outperform $30
Feb-07-20Initiated Jefferies Buy $25
Jan-10-20Initiated Nomura Buy $34
Dec-03-19Initiated William Blair Outperform
Jul-10-19Reiterated H.C. Wainwright Buy $60 → $41
Apr-30-19Downgrade Maxim Group Buy → Hold
Oct-25-18Reiterated Maxim Group Buy $48 → $35
May-23-22 10:15AM  
May-17-22 08:45AM  
Apr-28-22 07:00AM  
Apr-14-22 01:30PM  
09:04AM  
07:00AM  
Apr-08-22 08:00AM  
Jan-12-22 05:43AM  
Jan-11-22 04:05PM  
Dec-30-21 09:15AM  
08:00AM  
Dec-28-21 10:15AM  
Dec-15-21 10:23AM  
07:00AM  
Dec-14-21 07:50PM  
Dec-13-21 12:06PM  
Dec-10-21 08:00AM  
Dec-06-21 07:56PM  
Dec-03-21 03:04AM  
Dec-02-21 02:47PM  
10:25AM  
Dec-01-21 04:45PM  
01:39PM  
11:45AM  
08:36AM  
08:00AM  
Nov-24-21 08:00AM  
Nov-12-21 08:00AM  
Nov-10-21 07:00AM  
Oct-22-21 06:13AM  
Oct-21-21 07:00AM  
Oct-20-21 07:00AM  
Oct-15-21 06:50AM  
Sep-20-21 02:33PM  
12:09PM  
12:05PM  
07:30AM  
Sep-16-21 11:50AM  
07:00AM  
Sep-10-21 02:00PM  
08:25AM  
07:00AM  
Sep-09-21 07:00AM  
Sep-08-21 05:54PM  
Sep-07-21 08:00AM  
Aug-31-21 07:00AM  
Aug-27-21 12:57PM  
09:50AM  
Aug-26-21 04:14PM  
09:20AM  
07:00AM  
Aug-12-21 11:05AM  
Aug-10-21 08:00AM  
05:19AM  
Aug-04-21 04:39PM  
04:14PM  
01:10PM  
09:09AM  
08:08AM  
07:00AM  
05:45AM  
Jul-14-21 07:30AM  
Jul-08-21 08:00AM  
Jun-17-21 04:00PM  
06:30AM  
Jun-16-21 04:00PM  
08:00AM  
Jun-11-21 08:00AM  
Jun-10-21 07:00AM  
Jun-08-21 07:00AM  
Jun-07-21 07:00AM  
Jun-04-21 07:00AM  
Jun-01-21 07:00AM  
May-26-21 04:05PM  
May-24-21 07:30AM  
May-10-21 08:18AM  
Apr-30-21 06:01PM  
08:00AM  
07:00AM  
Apr-28-21 04:37PM  
Apr-27-21 11:22AM  
Apr-01-21 07:11AM  
Mar-31-21 11:21PM  
Mar-21-21 04:14AM  
Mar-11-21 04:01PM  
Jan-11-21 10:06AM  
Dec-29-20 03:27PM  
09:19AM  
08:00AM  
Dec-17-20 08:00AM  
Dec-10-20 08:00AM  
Nov-29-20 09:45AM  
Nov-24-20 08:59PM  
Nov-23-20 04:01PM  
Nov-19-20 08:00AM  
Nov-17-20 04:01PM  
08:00AM  
Nov-16-20 07:00AM  
Nov-13-20 04:46PM  
07:00AM  
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.